3/27
12:20 pm
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
Low
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
3/27
07:30 am
bcax
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/25
04:45 pm
bcax
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Medium
Report
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
3/13
12:12 pm
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.01 price target on the stock.
Low
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.01 price target on the stock.
3/12
08:07 pm
bcax
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth [Yahoo! Finance]
Low
Report
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth [Yahoo! Finance]
2/24
04:01 pm
bcax
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Medium
Report
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
2/12
10:57 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
Low
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
2/11
04:01 pm
bcax
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Low
Report
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2/7
06:17 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) was upgraded by analysts at Wedbush to a "strong-buy" rating.
2/6
07:33 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $31.00 price target on the stock.
Medium
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $31.00 price target on the stock.
1/27
08:02 am
bcax
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its price target raised by analysts at HC Wainwright from $42.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Bicara Therapeutics Inc. (NASDAQ: BCAX) had its price target raised by analysts at HC Wainwright from $42.00 to $45.00. They now have a "buy" rating on the stock.
1/27
08:00 am
bcax
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Low
Report
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium